{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T14:08:20Z","timestamp":1792850900528,"version":"4.5.0"},"reference-count":21,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T00:00:00Z","timestamp":1788912000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000650","name":"Institute of Cancer Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000650","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30 CA008748"],"award-info":[{"award-number":["P30 CA008748"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019450","name":"Verastem Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019450","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000272","name":"National Institute for Health and Care Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.ygyno.2026.09.003","type":"journal-article","created":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T20:33:19Z","timestamp":1789590799000},"page":"59-67","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Long-term efficacy and safety of avutometinib + defactinib in recurrent low-grade serous ovarian cancer: Results of a 2-year follow-up of ENGOT-OV60\/GOG-3052\/RAMP 201"],"prefix":"10.1016","volume":"213","author":[{"given":"Rachel N.","family":"Grisham","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Els","family":"Van Nieuwenhuysen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro D.","family":"Santin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00e9ronique","family":"D'Hondt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Premal H.","family":"Thaker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew R.","family":"Clamp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen N.","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol","family":"Aghajanian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Oaknin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"O'Malley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bradley J.","family":"Monk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicoletta","family":"Colombo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily N.","family":"Prendergast","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kari L.","family":"Ring","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Ray-Coquard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter G.","family":"Rose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlie","family":"Gourley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert W.","family":"Holloway","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hye Sook","family":"Chon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toon","family":"Van Gorp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hagop","family":"Youssoufian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin","family":"Salinas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Lustgarten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susana N.","family":"Banerjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2026.09.003_bb0005","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1136\/ijgc-2023-004610","article-title":"Low-grade serous ovarian cancer: expert consensus report on the state of the science","volume":"33.","author":"Grisham","year":"2023","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.ygyno.2026.09.003_bb0010","article-title":"Trends of low-grade serous ovarian carcinoma in the United States","volume":"29","author":"Matsuo","year":"2018","journal-title":"J. Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2026.09.003_bb0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajog.2008.01.035","article-title":"Epidemiology of low-grade serous ovarian cancer","volume":"198","author":"Plaxe","year":"2008","journal-title":"Am. J. Obstet. Gynecol."},{"key":"10.1016\/j.ygyno.2026.09.003_bb0020","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdw085","article-title":"Low-grade serous carcinoma of the ovary or peritoneum","volume":"27","author":"Gershenson","year":"2016","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ygyno.2026.09.003_bb0025","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.1002\/cncr.34903","article-title":"The highs and lows of serous ovarian cancer","volume":"129","author":"Grisham","year":"2023","journal-title":"Cancer"},{"key":"10.1016\/j.ygyno.2026.09.003_bb0030","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/j.ygyno.2019.12.033","article-title":"Low-grade serous ovarian cancer: state of the science","volume":"156","author":"Slomovitz","year":"2020","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2026.09.003_bb0035","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1111\/aogs.14518","article-title":"Stage, treatment and survival of low-grade serous ovarian carcinoma in the Netherlands: a nationwide study","volume":"102","author":"De Decker","year":"2023","journal-title":"Acta Obstet. Gynecol. Scand."},{"key":"10.1016\/j.ygyno.2026.09.003_bb0040","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/j.ygyno.2021.11.019","article-title":"The genomic landscape of low-grade serous ovarian\/peritoneal carcinoma and its impact on clinical outcomes","volume":"165","author":"Gershenson","year":"2022","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2026.09.003_bb0045","doi-asserted-by":"crossref","first-page":"4456","DOI":"10.1158\/1078-0432.CCR-21-4183","article-title":"MAPK pathway genetic alterations are associated with prolonged overall survival in low-grade serous ovarian carcinoma","volume":"28","author":"Manning-Geist","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ygyno.2026.09.003_bb0050","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/S0140-6736(21)02175-9","article-title":"Trametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer (GOG 281\/LOGS): an international, randomised, open-label, multicentre, phase 2\/3 trial","volume":"399","author":"Gershenson","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.ygyno.2026.09.003_bb0055","author":"National Comprehensive Care Network"},{"key":"10.1016\/j.ygyno.2026.09.003_bb0060","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.1200\/JCO.2015.61.0873","article-title":"Impact of age and primary disease site on outcome in women with low-grade serous carcinoma of the ovary or peritoneum: results of a large single-institution registry of a rare tumor","volume":"33","author":"Gershenson","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2026.09.003_bb0065","doi-asserted-by":"crossref","first-page":"3753","DOI":"10.1200\/JCO.20.01164","article-title":"MILO\/ENGOT-ov11: binimetinib versus physician\u2019s choice chemotherapy in recurrent or persistent low-grade serous carcinomas of the ovary, fallopian tube, or primary peritoneum","volume":"38","author":"Monk","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2026.09.003_bb0070","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.ygyno.2022.09.022","article-title":"Genomic profiling in low grade serous ovarian cancer: identification of novel markers for disease diagnosis and therapy","volume":"167","author":"ElNaggar","year":"2022","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2026.09.003_bb0075","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.ygyno.2024.01.028","article-title":"Preclinical efficacy of RAF\/MEK clamp avutometinib in combination with FAK inhibition in low grade serous ovarian cancer","volume":"183","author":"McNamara","year":"2024","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2026.09.003_bb0080","doi-asserted-by":"crossref","first-page":"2782","DOI":"10.1200\/JCO-25-00112","article-title":"Efficacy and safety of avutometinib \u00b1 defactinib in recurrent low-grade serous ovarian cancer: primary analysis of ENGOT-OV60\/GOG-3052\/RAMP 201","volume":"43","author":"Banerjee","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2026.09.003_bb0085","series-title":"AVMAPKI\u2122 FAKZYNJA\u2122 CO-PACK (Avutometinib Capsules; Defactinib Tablets, Co-Packaged for Oral Use)","author":"Verastem.","year":"2025"},{"key":"10.1016\/j.ygyno.2026.09.003_bb0090","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1097\/AOG.0000000000001867","article-title":"Outcomes of women with high-grade and low-grade advanced-stage serous epithelial ovarian cancer","volume":"129","author":"Gockley","year":"2017","journal-title":"Obstet. Gynecol."},{"key":"10.1016\/j.ygyno.2026.09.003_bb0095","doi-asserted-by":"crossref","first-page":"3074","DOI":"10.1038\/s41591-025-03763-y","article-title":"Defactinib with avutometinib in patients with solid tumors: the phase 1 FRAME trial","volume":"31","author":"Banerjee","year":"2025","journal-title":"Nat. Med."},{"key":"10.1016\/j.ygyno.2026.09.003_bb0100","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1158\/1078-0432.CCR-25-3042","article-title":"Molecular profiling and tumour biomarker analysis of GOG281\/LOGS: a positive late-phase trial of trametinib for recurrent\/persistent low grade-serous ovarian cancer","volume":"32","author":"Hollis","year":"2026","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ygyno.2026.09.003_bb0105","author":"ClinicalTrials.gov"}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825826021268?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825826021268?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T01:12:39Z","timestamp":1792804359000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825826021268"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":21,"alternative-id":["S0090825826021268"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2026.09.003","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-term efficacy and safety of avutometinib + defactinib in recurrent low-grade serous ovarian cancer: Results of a 2-year follow-up of ENGOT-OV60\/GOG-3052\/RAMP 201","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2026.09.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}